Choosing targetable pathogenetic pathways? - Vienna 2024

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

International Congresses Vienna 2024 Choosing targetable pathogenetic pathways?

Interstitial lung diseases

Chair(s): Katerina Antoniou, Marlies S. Wijsenbeek, Antoine Froidure

Session type: State of the art session

Choosing targetable pathogenetic pathways?

Manuela Funke-Chambour

EVENTS HOME

Replay
Slides

Previous presentation

Next presentation

Session content

Failed idiopathic pulmonary fibrosis trials: lessons learned

Luca Richeldi

Replay

Slides

Beyond forced vital capacity: prime time for patient-reported outcomes

Yet Hong Khor

Replay

Slides

Choosing targetable pathogenetic pathways?

Manuela Funke-chambour

Replay

Slides

Clinical trials on acute exacerbations

Bruno Crestani

Replay

Slides

Discussion and Q&A

Replay

Session aims

To focus on understanding the lessons learned from the failed trials and how drug development can be improved for IPF; to present novel endpoints different from forced vital capacity decline.

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}